Some scientific research about 57825-30-6

From this literature《Discovery of Orally Available Runt-Related Transcription Factor 3 (RUNX3) Modulators for Anticancer Chemotherapy by Epigenetic Activation and Protein Stabilization》,we know some information about this compound(57825-30-6)Related Products of 57825-30-6, but this is not all information, there are many literatures related to this compound(57825-30-6).

Related Products of 57825-30-6. The fused heterocycle is formed by combining a benzene ring with a single heterocycle, or two or more single heterocycles. Compound: 1-(Bromomethyl)-4-ethylbenzene, is researched, Molecular C9H11Br, CAS is 57825-30-6, about Discovery of Orally Available Runt-Related Transcription Factor 3 (RUNX3) Modulators for Anticancer Chemotherapy by Epigenetic Activation and Protein Stabilization. Author is Yang, Jee Sun; Lee, Chulho; Cho, Misun; Kim, Hyuntae; Kim, Jae Hyun; Choi, Seonghwi; Oh, Soo Jin; Kang, Jong Soon; Jeong, Jin-Hyun; Kim, Hyun-Jung; Han, Gyoonhee.

Recently, the authors identified a novel strategy for anticancer chemotherapy by restoring runt-related transcription factor 3 (RUNX3) levels via lactam-based histone deacetylase (HDAC) inhibitors that stabilize RUNX3. Described here are the synthesis, biol. evaluation, and pharmacokinetic evaluation of new synthetic small mols. based on pyridone-based HDAC inhibitors that specifically stabilize RUNX3 by acetylation and regulate its function. Many of the newly synthesized compounds showed favorable RUNX activities, HDAC inhibitory activities, and inhibitory activities on the growth of human cancer cell lines. Notably, one of these new derivatives, I , significantly restored RUNX3 in a dose-dependent manner and showed high metabolic stability, a good pharmacokinetic profile with high oral bioavailability and long half-life, and strong antitumor activity. This study suggests that pyridone-based analogs modulate RUNX3 activity through epigenetic regulation as well as strong transcriptional and post-translational regulation of RUNX3 and could be potential clin. candidates as orally available RUNX3 modulators for the treatment of cancer.

From this literature《Discovery of Orally Available Runt-Related Transcription Factor 3 (RUNX3) Modulators for Anticancer Chemotherapy by Epigenetic Activation and Protein Stabilization》,we know some information about this compound(57825-30-6)Related Products of 57825-30-6, but this is not all information, there are many literatures related to this compound(57825-30-6).

Reference:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider